OPM integrated the LRRK2 Investigative Therapeutics Exchange program from The Michael J. Fox Foundation

OPM integrated the LRRK2 Investigative Therapeutics Exchange program from The Michael J. Fox Foundation

Dijon, France, September 25, 2025, at 6:00 pm CEST – Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, today announces it has joined The Michael J. Fox Foundation for Parkinson’s Research’s program the (MJFF) LRRK2 Investigative Therapeutics Exchange (LITE).